Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FAT1 siRNA
- Development stage
- Preclinical
- Lead developer
- AIIMS New Delhi
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
FAT1 siRNA is a small interfering RNA (siRNA) designed to target and silence the expression of the FAT1 (FAT atypical cadherin 1) gene. FAT1 is an atypical cadherin that has been identified as an oncogene in various cancers, including glioblastoma, where it promotes tumor growth and maintains an immunosuppressive microenvironment. By silencing FAT1, this siRNA reduces the expression of pro-inflammatory and anti-inflammatory cytokines (such as TGF-β, IL-10, and PD-L1), thereby potentially reversing the immunosuppressive milieu and inhibiting gliomagenesis. This research is primarily associated with the All India Institute of Medical Sciences (AIIMS) and is currently in the preclinical stage of development.
- Other names
- FAT1-specific siRNAFAT-1-specific siRNAFAT 1-specific siRNA
02
Targets
FAT1 (FAT atypical cadherin 1)
Beyond the preview
Go deeper on FAT1 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FAT1 siRNA.